Navigation Links
Personalised Medicine: An Opportunity for Investment
Date:1/14/2009

LONDON, Jan. 14 /PRNewswire/ -- The pharmaceutical industry is currently facing some key challenges. The increase in drug development costs, a decrease in the number of drugs being approved, and scrutiny from regulatory authorities are forcing companies to look at alternative revenue generators. Patients themselves are also demanding more effective and safer drugs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Pharmacogenomics therefore presents a convincing alternative to guide drug development and therapy. Pharmacogenomics deals with the influence of genetic variations on drug response in patients by correlating gene expression with a drug's efficacy. Personalised medicine is the result of individualised pharmacotherapy, which allows the formulation of drugs that offer appropriate treatment to the right person as needed.

"Recent reports of mishaps taking place due to improper drug metabolism, even when taken at optimal dose, have forced companies to consider individualised medicine more of a necessity than a mere research project," notes Frost & Sullivan (http://www.drugdiscovery.frost.com) Research Analyst Prabakar Sampath. "Every year several hundreds of patients either do not benefit from the treatment they are provided or develop adverse reactions to it. These are compelling reasons enough to pursue personalised medicine as a future directive."

Critics of personalised medicine often suggest that interest in research for a given pharmacogenomics study would decrease because it would only serve a niche market. They contend that a personalised approach would reduce new patient trials for some therapies.

However, a reduction in initial sales will be compensated by greater compliance, leading to higher product use. Frost & Sullivan believes that the commercial feasibility of personalised medicine is not what is gained or lost by moving forward, but what is at stake by not moving forward.

"The desire to meet patients' unmet medical needs, the necessity for product differentiation to gain market share and reimbursement in increasingly crowded markets in several therapeutic areas are forcing companies to invest in pharmacogenomics research," notes Sampath.

Already, genetic testing has been made easy with the increase in availability of reagents and pharmacogenetics services. Diagnostic laboratories are marketing pharmacogenomics services to physicians and in some cases, patients too.

"An ideal application of pharmacogenomics is to integrate it into clinical and nonclinical studies in order to provide value to pharmaceutical R&D by supplementing the information from these studies," says Sampath. "The goal is to provide safer and more efficient medicines, combined with diagnostics, in order to meet the needs of patients."

Pharmacogenomics provides a novel area for product differentiation, competitive advantage, and enhancement of R&D productivity. The pharmaceutical industry is learning how to best apply it in its R&D programs.

Recent initiatives, such as the formation of several pharmacogenomics-focused consortia, new regulatory guidance documents, the introduction of legislative bills and high-profile safety concerns continue to illustrate the prominent role pharmacogenomics will play in moving drug development and therapy from a population-based to an individualized paradigm.

If you are interested in more information on Frost & Sullivan's analysis of drug discovery markets, then send an e-mail to Patrick Cairns, Corporate Communications, at patrick.cairns@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, more details will be provided.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership(TM) empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnership Services, visit http://www.frost.com.

    Contact:
    Patrick Cairns
    Corporate Communications - Europe & Africa
    P: +27 18 468 2315
    E: patrick.cairns@frost.com

   http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention
2. U.S. Preventive Medicine: Knowing Risk Factors & Early Detection are Best Strategies for Colon Cancer Prevention
3. Personalizing medicine: New research shows potential of targeted therapies for cancer
4. Measuring medicine: How new technologies could help doctors predict patient outcomes
5. The Changing Face of Medicine: National Medical Fellowships Annual Awards Gala Honors Three Fellows
6. Florida and California Represent Equivalent Areas of Opportunity in the Alzheimers Disease Drug Market
7. Renowned Cancer Researcher Dan Von Hoff, M.D. Advocates for 'The Lost Opportunity in Phase I Oncology Trials'
8. Usher Teams With Body By Milk to Give Teens Once-in-a-Lifetime Opportunity
9. ECPI College of Technology and Medical Careers Institute Announce Extension for South Carolina Military Scholarship Opportunity
10. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
11. HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: